Biotechnology & Life Sciences

Stock Code

BNE

Stock Exchange

ax

Bone Medical (BNE), along with its subsidiaries, is engaged in the development of therapeutics to prevent and/or treat bone and joint diseases and conditions, especially osteoporosis, osteoarthritis and arthritis. The Company operates in the biopharmaceutical segment in Australia. The Company’s wholly owned subsidiaries include Bone Limited and Owein Pty Ltd. Bone Limited has license agreements for the technologies of Axcess, Mozaic, Vaxcine, and Lexicon from the licensors Axcess Limited, Mozaic Discovery Limited, Vaxcine Limited and Lexicon Limited.

Stock Code

BIT

Stock Exchange

ax

Biotron Limited (BIT) was established to develop research projects on the basis of intellectual property (IP) developed at the Australian National University's John Curtin School of Medical Research (JCSMR). The company’s core focus is on the licensing of compounds arising from these research projects to third parties, such as pharmaceutical companies, for eventual commercialisation. Key projects under development include a cancer diagnostic test and anti-viral agents for use in the treatment of HIV.

Stock Code

BTC

Stock Exchange

ax

Biotech Capital (BTC) is one of Australia's largest biotechnology investment companies. BTC invests in a range of small- to medium-sized biotechnology companies, both listed and unlisted. The company aims to build a portfolio of 10-20 high-quality companies. The company also utilises the services of Foursight Associates (Scientific Adviser). Foursight evaluates investment proposals from a scientific and biomedical standpoint and produces reports providing assessments of the technical merits of the proposed proposals. BTC was listed on the ASX in August 2000.

Stock Code

BOS

Stock Exchange

ax

BioSignal (BOS) was established to commercialise a proprietary technology based on anti-bacterial and anti-fouling compounds called "furanones" found in a seaweed. BOS's Furanones are naturally derived compounds that reduce a bacteria’s ability to attach to innate surfaces (such as pipes, ship hulls) and animate surfaces (such as lungs, skin and teeth). Product applications include anti-bacterial contact lenses; marine anti-fouling paints; industrial products; skin care products; and aqueous products. The company was listed on the ASX in April 2004.

Stock Code

BPO

Stock Exchange

ax

BioProspect (BPO) is a Brisbane based company focused on the discovery of new pharmaceutical, nutraceutical and agrochemical products from natural sources. It has an established Natural Extract Library representing a collection of materials from some of the most unique and diverse flora and fauna in the world. These collections are screened for biological activity and those successful samples form the building blocks for lead compound discovery and new pharmaceuticals, nutraceuticals and agrochemicals. BioProspect was established in 1998 and listed on the ASX in January 2001.

Stock Code

BNO

Stock Exchange

ax

Bionomics (BNO) is a biotechnology company creating small molecule drugs to treat cancer and disorders of the central nervous system. The company has drug discovery programs in four therapeutic areas: Cancer (Vascular Targeting Agents), Multiple Scelrosis, Anxiety/Epilepsy and Cancer (Angiogenesis). Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers to development treatments for cancer and serious disorders of the nervous system. Initially technology platforms were established in the genomics of epilepsy, angiogenesis and breast cancer.

Stock Code

BDM

Stock Exchange

ax

BioDiem is a Melbourne-based pharmaceutical development company, developing a portfolio of promising later stage projects from world-class research institutes.

Stock Code

BLT

Stock Exchange

ax

Benitec (BLT) is a biotechnology research and development company, involved in developing therapeutics for serious diseases. BLT has developed a technology that uses DNA directed RNA interference (ddRNAi) to trigger the natural gene silencing process. The technology has potential application in the treatment of various diseases, including cancer, HIV, hepatitis C, autoimmune disorders. R&D and clinical operations are centred in California, USA. BLT was listed on the ASX in 1997. In September 2002, the company first demonstrated its gene silencing technology in animals.

Stock Code

ACU

Stock Exchange

ax

ACU is an international biotechnology company developing a product portfolio of a broad range of oncology-related products. The company is currently involved in a pancreatic cancer drug (RP101), which is in phase II clinical studies, and Pentry's anti-cancer vaccine, which is being evaluated in prostate cancer patients. Pentry targets one of the most common defects in cancer cells - a mutated p53 gene. Acuvax Limited (ACU) was listed on the ASX in August 1971. Its headquarters are situated in Sydney. ACU was renamed to its current name in December 2008.

Stock Code

POH

Stock Exchange

ax

Phosphagenics (POH) is a biotechnology company. The Company focuses on the research, development and commercialisation of products for the nutraceutical and pharmaceutical industries. Phosphagenics listed on the Australian Stock Exchange on 9th August, 1993. It is also listed on the London Stock Exchange's Alternative Investment Market under the stock code PSG. The Company’s head office is located in Melbourne.